NCT06375642View on ClinicalTrials.gov

A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Intrahepatic Cholangiocarcinoma
Interventions
DRUG

Adebrelimab

Adebrelimab, Surufatinib and HAIC

Trial Locations (1)

300308

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06375642 - A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | Biotech Hunter | Biotech Hunter